ArticleNature2011
Selective killing of cancer cells by a small molecule targeting the stress response to ROS.
Article in Nature, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 453 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
453 citing papers in PubMed, 1,028 citations in OpenAlex.
- Selective TRPV2 Antagonists Derived from the Natural Product Piperlongumine Inhibit Cancer Cell Migration and Metastasis.ACS chemical biology · 2026Article
- Piperlongumine suppresses YAP-ET-1-CXCL2 signaling to modulates aggressiveness of triple-negative breast cancer cells.Translational oncology · 2026Article
- Migrasomes: A Novel Target for Cancer Treatment.Current cancer drug targets · 2026Review
- Polychlorinated biphenyls and breast cancer: evidence, mechanisms, and risk management.Frontiers in cell and developmental biology · 2026Review
- Piperlongumine induces meningioma cell death via the ROS-mediated endoplasmic reticulum stress and the alteration of the ubiquitin-proteasome system.Journal of neuro-oncology · 2025Article
- Iron-Catalyzed Carbonylation Reactions with Carbon Monoxide.Angewandte Chemie (International ed. in English) · 2025Review
- MAI-TargetFisher: A proteome-wide drug target prediction method synergetically enhanced by artificial intelligence and physical modeling.Acta pharmacologica Sinica · 2025Article
- Herbicidal Activity and Metabolic Profiling ofJournal of agricultural and food chemistry · 2025Article
- Cellular senescence in the tumor with a bone niche microenvironment: friend or foe?Clinical and experimental medicine · 2025Review
- Gold nanorod-based engineered nanogels for cascade-amplifying photothermo-enzymatic synergistic therapy.Journal of pharmaceutical analysis · 2024Article
- Catalytic activity of violet phosphorus-based nanosystems and the role of metabolites in tumor therapy.Nature communications · 2024Article
- Current advances and future trends of hormesis in disease.npj aging · 2024Review
- Immunoactivation by Cutaneous Blue Light Irradiation Inhibits Remote Tumor Growth and Metastasis.ACS pharmacology & translational science · 2024Article
- Electrophilic Compounds in the Human Diet and Their Role in the Induction of the Transcription Factor NRF2.International journal of molecular sciences · 2024Review
- Citrus Carotenoid Extracts Promote ROS Accumulation and Induce Oxidative Stress to Exert Anti-Proliferative and Pro-Apoptotic Effects in MDA-MB-231 Cells.Antioxidants (Basel, Switzerland) · 2024Article
- Comparative assessment of direct and indirect cold atmospheric plasma effects, based on helium and argon, on human glioblastoma: an in vitro and in vivo study.Scientific reports · 2024Article
- Preparation, Characterization, and Evaluation of the Anticancer Effect of Mesoporous Silica Nanoparticles Containing Rutin and Curcumin.Pharmaceutical nanotechnology · 2024Article
- Combination ofFrontiers in pharmacology · 2024Article
- Unlocking Potentially Therapeutic Phytochemicals in Capadulla (Metabolites · 2023Article
- Citrus Carotenoid Extracts Exert Anticancer Effects through Anti-Proliferation, Oxidative Stress, and Mitochondrial-Dependent Apoptosis in MCF-7 Cells.Foods (Basel, Switzerland) · 2023Article
393 more citing papers are in PubMed but not listed here.
Corrections and comments
- Correction · 2015-09-16Error in Data · Error in Text · Lack of IRB/IACUC Approval and/or Compliance · Updated to Retraction · · see also: https://www.nature.com/news/protection-priority-1.18354
- Correction · 2012-01-25Error in Data · Error in Methods · Error in Text · Updated to Retraction · · see also: https://www.nature.com/news/protection-priority-1.18354
- Retraction · 2018-07-25Concerns/Issues about Data · Concerns/Issues about Image · Concerns/Issues about Results and/or Conclusions · Objections by Author(s) · Original Data and/or Images not Provided and/or not Available · Upgrade/Update of Prior Notice(s) · · see also: https://www.nature.com/news/protection-priority-1.18354
- Commented on by
- Commented on by
- Erratum issued
- Erratum issued
- Retracted
Authors and funding
14 authors at 3 institutions in 1 country.
Funding
Abstract
Malignant transformation, driven by gain-of-function mutations in oncogenes and loss-of-function mutations in tumour suppressor genes, results in cell deregulation that is frequently associated with enhanced cellular stress (for example, oxidative, replicative, metabolic and proteotoxic stress, and DNA damage). Adaptation to this stress phenotype is required for cancer cells to survive, and consequently cancer cells may become dependent upon non-oncogenes that do not ordinarily perform such a vital function in normal cells. Thus, targeting these non-oncogene dependencies in the context of a transformed genotype may result in a synthetic lethal interaction and the selective death of cancer cells. Here we used a cell-based small-molecule screening and quantitative proteomics approach that resulted in the unbiased identification of a small molecule that selectively kills cancer cells but not normal cells. Piperlongumine increases the level of reactive oxygen species (ROS) and apoptotic cell death in both cancer cells and normal cells engineered to have a cancer genotype, irrespective of p53 status, but it has little effect on either rapidly or slowly dividing primary normal cells. Significant antitumour effects are observed in piperlongumine-treated mouse xenograft tumour models, with no apparent toxicity in normal mice. Moreover, piperlongumine potently inhibits the growth of spontaneously formed malignant breast tumours and their associated metastases in mice. Our results demonstrate the ability of a small molecule to induce apoptosis selectively in cells that have a cancer genotype, by targeting a non-oncogene co-dependency acquired through the expression of the cancer genotype in response to transformation-induced oxidative stress.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.